TY - JOUR
T1 - A scoring instrument to predict the survival prognoses of patients with metastatic epidural spinal cord compression from gynecological malignancies
AU - Janssen, Stefan
AU - Bajrovic, Amira
AU - Schild, Steven E.
AU - Rades, Dirk
N1 - Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 2016/10
Y1 - 2016/10
N2 - Aim: To design a scoring instrument for rating overall survival (OS) of patients with metastatic epidural sinal cord compression (MESCC) from gynecological malignancies. Patients and Methods: In 22 patients treated with radiotherapy alone for MESCC from gynecological malignancies, ten factors were analyzed for effects on OS. Factors significantly associated with OS on multivariate analysis were included in a scoring instrument. Results: On multivariate analyses, no visceral metastases (p=0.004) and affection of 1-2 vertebrae (p=0.012) were significant. Scoring points for each factor were 0 or 1, depending on OS rates. After summing, scores of 0 (n=6), 1 (n=9) or 2 points (n=9) were obtained. OS rates were 0%, 78% and 100%, respectively, at 3 months and 0%, 33% and 86%, respectively, at 6 months (p<0.001). Conclusion: An instrument was developed for estimating the lifespan of patients with MESCC from gynecological malignancies. This instrument can support physicians when picking an individual treatment.
AB - Aim: To design a scoring instrument for rating overall survival (OS) of patients with metastatic epidural sinal cord compression (MESCC) from gynecological malignancies. Patients and Methods: In 22 patients treated with radiotherapy alone for MESCC from gynecological malignancies, ten factors were analyzed for effects on OS. Factors significantly associated with OS on multivariate analysis were included in a scoring instrument. Results: On multivariate analyses, no visceral metastases (p=0.004) and affection of 1-2 vertebrae (p=0.012) were significant. Scoring points for each factor were 0 or 1, depending on OS rates. After summing, scores of 0 (n=6), 1 (n=9) or 2 points (n=9) were obtained. OS rates were 0%, 78% and 100%, respectively, at 3 months and 0%, 33% and 86%, respectively, at 6 months (p<0.001). Conclusion: An instrument was developed for estimating the lifespan of patients with MESCC from gynecological malignancies. This instrument can support physicians when picking an individual treatment.
UR - http://www.scopus.com/inward/record.url?scp=84991811299&partnerID=8YFLogxK
U2 - 10.21873/anticanres.11127
DO - 10.21873/anticanres.11127
M3 - Journal articles
C2 - 27798917
AN - SCOPUS:84991811299
SN - 0250-7005
VL - 36
SP - 5469
EP - 5472
JO - Anticancer Research
JF - Anticancer Research
IS - 10
ER -